News round-up for 25-29 September by DDW Digital Content Editor Diana Spencer.
Immunotherapy has taken centre stage this week, with several announcements relating to regulatory approval, investment and research results for antibody and CAR-T therapies, perhaps most significantly, encouraging early-stage data for the first in vivo CAR-T therapy.
The top stories:
€27.3M to advance monoclonal antibody for autoimmune diseases
AbolerIS Pharma has raised €27.3 million in a Series A financing led by Caixa Capital Risc and co-led by Sound Bioventures and Newton Biocapital.
AACR Cancer Progress Report with spotlight on cancer immunotherapy
On 13 September 2023, the American Association for Cancer Research (AACR) released the AACR Cancer Progress Report 2023: Advancing the Frontiers of Cancer Science and Medicine.
Positive early-stage results for in vivo CAR-T technology
Umoja Biopharma has revealed data from an ongoing non-human primate (NHP) study demonstrating effective, durable, and well tolerated in vivo chimeric antigen receptor (CAR) T cell generation using the company’s VivoVec platform.
FDA fast-tracks ADC for non-small cell lung cancer
The US Food and Drug Administration (FDA) has granted fast track designation to Mythic Therapeutics’ investigational cMET-targeting ADC, MYTX-011, for the treatment of patients with non-small cell lung cancer (NSCLC) with cMET overexpression.
CAR-T therapy targets over 80% of human tumours
Leucid Bio has been granted clinical trial authorisation by the UK’s MHRA to initiate a Phase I/II clinical trial evaluating autologous NKG2D-targeted CAR-T cell therapy, LEU011, in patients with relapsed or refractory solid tumours.
